ixekizumab + tirzepatide

**Ixekizumab + tirzepatide** is an investigational combination therapy currently being evaluated in clinical trials primarily for **moderate to severe plaque psoriasis** and **psoriatic arthritis** in overweight or obese patients with weight-related comorbidities[1][3][7][9][10]. Ixekizumab is a humanized monoclonal antibody that targets and neutralizes interleukin-17A (IL-17A), a key inflammatory cytokine involved in the pathogenesis of psoriasis and other inflammatory diseases[8]. Tirzepatide is a synthetic peptide serving as a dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide 1 (GLP-1) receptor, effectively regulating blood glucose, promoting insulin secretion, reducing appetite, and resulting in significant weight loss[2][4][6]. The rationale for combining these modalities is to simultaneously address immune-mediated inflammation and metabolic dysfunction in patients with psoriasis and obesity, potentially improving both skin and systemic outcomes[1][5][7][9].

Brand names

TaltzMounjaroZepbound

Other names

tirzepatideixekizumab